Tesofensine

Reference only, for adults researching investigational appetite-suppressant pharmacology. It is not an approved medication anywhere for general obesity, it has no long-term safety data, and it is not a reasonable self-directed weight-loss protocol — approved GLP-1 agents have vastly better evidence and physician oversight.

Tesofensine is a small-molecule inhibitor of the presynaptic transporters for noradrenaline, dopamine, and serotonin — a triple reuptake inhibitor, or SNDRI. It was originally developed for Parkinson's and Alzheimer's disease, failed in those indications, and was repurposed when weight loss appeared as a side effect. Raising synaptic monoamines in hypothalamic and mesolimbic circuits suppresses appetite and increases energy expenditure; more recent rodent work has traced part of the effect to silencing of GABAergic neurons in the lateral hypothalamus.

0 mg, or placebo once daily for 24 weeks. 6% on the three ascending doses. The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia.

5 mg group. The authors explicitly stated their efficacy and safety findings needed confirmation in phase III — confirmation that did not follow for general obesity. PubMed's record for this trial also carries a 2013 Lancet expression of concern, which should be weighed when reading it.

3% weight loss versus placebo over 24 weeks with no significant heart-rate or blood-pressure difference, though sleep disturbance, dry mouth, and headache were markedly more common on treatment and one participant discontinued for exacerbated pre-existing anxiety. Tesofensine is a CYP3A4 substrate with a long elimination half-life, which makes it vulnerable to interaction with CYP3A4 inhibitors.

Appetite suppression is reported early, but the trial endpoints were measured at 24 weeks. The compound has a long, multi-day elimination half-life, so blood levels accumulate for weeks after a dose change and adverse effects do not clear quickly on stopping.

Nothing, on a self-directed basis. The one combination studied clinically is Tesomet, a fixed 0.5 mg tesofensine / 50 mg metoprolol combination in which the beta-blocker was added specifically to blunt the cardiovascular effects — which tells you what the underlying risk is. It must not be combined with SSRIs, SNRIs, MAOIs, or other serotonergic agents, or with stimulants.

1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trialPubMed · 2008
2. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesityPubMed · 2022
3. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazolePubMed · 2010
4. PubChem - Tesofensine Compound Summary, CID 11370864PubChem · 2026